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(3+3) was classified as grade 1 which better reflected the mostly indolent behaviour of these tumours.
Another issue discussed at the meeting and subsequently endorsed was that in Gleason score 7 cases, the
percentage pattern 4 should be recorded. This is especially important in situations where modern active
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Summary
The Gleason Grading system has been used for over 50
years to prognosticate and guide the treatment for patients
with prostate cancer. At consensus conferences in 2005
and 2014 under the guidance of the International Society
of Urological Pathology (ISUP), the system has undergone
major modifications to reflect modern diagnostic and
therapeutic practices. The 2014 consensus conference
yielded recommendations regarding cribriform, mucinous,
glomeruloid and intraductal patterns, the most significant
of which was the removal of any cribriform pattern from
Gleason grade 3. Furthermore, a Gleason score grouping
system was endorsed which consisted of five grades
where Gleason score 6 (3+3) was classified as grade 1
which better reflected the mostly indolent behaviour of
these tumours. Another issue discussed at the meeting
and subsequently endorsed was that in Gleason score 7
cases, the percentage pattern 4 should be recorded. This
is especially important in situations where modern active
surveillance protocols expand to include men with low
volume pattern 4. While major progress was made at the
conference, several issues were either not resolved or not
discussed at all. Most of these items relate to details of
assignment of Gleason score and ISUP grade in specific
specimen types and grading scenarios. This detailed
review looks at the 2014 ISUP conference results and
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subsequent literature from an international perspective
and proposes several recommendations. The specific
issues addressed are percentage pattern 4 in Gleason
score 7 tumours, percentage patterns 4 and 5 or 4/5 in
Gleason score 8–10 disease, minor (5%) high grade
patterns when either 2 or 3 patterns are present, level of
reporting (core, specimen, case), dealing with grade di-
versity among site (highest and composite scores) and
reporting scores in radical prostatectomy specimens with
multifocal disease. It is recognised that for many of these
issues, a strong evidence base does not exist, and further
research studies are required. The proposed recommen-
dations mostly reflect consolidated expert opinion and they
are classified as established if there was prior agreement
by consensus and provisional if there was no previous
agreement or if the item was not discussed at prior
consensus conferences. For some items there are
reporting options that reflect the local requirements and
diverse practice models of the international urological pa-
thology community. The proposed recommendations pro-
vide a framework for discussion at future consensus
meetings.
Key words: Prostate adenocarcinoma; grading; ISUP grade; Gleason; Inter-
national Society of Urological Pathology.
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INTRODUCTION
In November 2014, the International Society of Urological
Pathology (ISUP) hosted a consensus conference on Gleason
grading which was attended by 82 invited experts in prostate
cancer from 19 countries.1 The purpose of the meeting was to
update the grading system for prostate cancer which had last
been formally modified by the ISUP in 2005.2 Certain
grading issues had not been resolved at the earlier consensus
meeting and in the ensuing decade new research data has
been published. In addition, there was pressure from epide-
miologists and public health experts to contain the ‘over-
diagnosis and over-treatment’ of prostate cancer. Further-
more, active surveillance is now being embraced by many in
the urology and oncology communities as a preferred
approach in patients with low grade and low volume cancer.3
In view of this, guidelines were needed to clarify grading
criteria for low grade prostate cancer, in order to more
accurately identify patients suitable for enrolment into active
surveillance programs.
At the 2014 meeting many issues were addressed,
including refinements in the assignment of patterns that
comprise the Gleason grades, the most important of which
was that no cribriform pattern was to be classified as Gleason
grade 3. A novel Gleason diagram was developed incorpo-
rating the changes for which there was consensus (Fig. 1). A
major part of the meeting was devoted to the endorsement of
a five level prognostic grading system based upon the criteria
of the 2005 ISUP modification of Gleason scores and grades.
Numerous studies have, in the past, argued for the estab-
lishment of a grading system for prostate cancer based upon
the grouping of Gleason criteria.4 Importantly, the classifi-
cation adopted at the 2014 ISUP conference, while unique in
itself, did include a number of recommendations dating back
to the groupings proposed by Gleason in 1977.5 Following
the consensus conference the prognostic significance of the
grading system accepted by the delegates has been validated
in separate studies.6–9 The name of the grouping system was
controversial from the outset. The 2016 World Health Or-
ganization (WHO) blue book avoided recommending a
formal nomenclature and used the descriptive term ‘grade
group’.10 While this term was subsequently used in the
American Joint Committee on Cancer (AJCC) TNM8
Manual, the ‘ISUP grade’ is the official term endorsed by the
ISUP Council in March 2015.4,11 This naming was in keep-
ing with prior grading systems such as for urothelial carci-
noma12 and renal cell carcinoma,13 and the renal tumour
classification system14 resulting from ISUP sponsored
consensus conferences. ISUP grade is also the recommended
terminology in the International Collaboration of Cancer
Reporting (ICCR) datasets for reporting of prostate cancer,
which outline minimum requirements for the reporting of
cancer specimens.15–18 Aside from the naming matter, there
are several emerging and controversial issues that were not
fully addressed in the published report of the 2014 confer-
ence.1 Some of these matters were discussed, at least in part,
at the consensus conference and others have been raised
subsequently. Many issues relate to the specific rules of
assigning Gleason scores, ISUP grades and derivative mea-
surements (Table 1).
It is acknowledged that in a recent publication, selected
practical issues for implementing conference recommenda-
tions are discussed by a sub-group of the organising com-
mittee.19 Our current review presents a detailed discussion of
controversial issues emanating from the 2014 conference and
subsequent literature and proposes reporting guidelines for
everyday practice. Additionally, areas for future research are
highlighted.
Emerging issues that will not be dealt with here include the
prognostic significance of sub-patterns of Gleason grades 4
and 5, and specifically whether the presence of intraductal
carcinoma and/or invasive cribriform carcinoma should
affect assignment of the Gleason score and ISUP grade.
These topics will be addressed at a future ISUP consensus
conference, along with the potential of using image analysis
algorithms based on machine learning as decision support
tools in the grading of prostate cancer.
There is recognition of the diversity of urological pathol-
ogy practice globally, based on local clinical expectations,
practice settings and available resources. The content of this
manuscript has been reviewed by a diverse group of inter-
national experts in prostatic pathology and the recommen-
dations are constructed in a manner to allow some flexibility
in their international implementation.
PERCENTAGE (%) PATTERN 4 IN GLEASON
SCORE 7 CASES
The value of subdividing Gleason score 7 cancers into two
categories with primary pattern 3 (GS 3+4=7) or 4 (GS
4+3=7) is well established20,21 and indeed modern nomo-
grams and risk calculators incorporate this split.22,23 The
ISUP grading system formally recognises this subdivision
with Gleason 3+4=7 being ISUP grade 2 and 4+3=7 ISUP
grade 3. The amount of Gleason pattern 4 in a score 7 case is a
continuous variable and there are some compelling reasons
why a finer stratification is important.24–26 The clinicians in
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attendance at the 2014 consensus conference agreed that
reporting the % pattern 4 present would be helpful for patient
management. While the issue was not voted on at the
consensus conference, post-conference polling of the at-
tendees showed widespread support for including this
measurement in pathology reports. The 2016 WHO blue
book also recommends that % pattern 4 be recorded in GS 7
cases.10 Furthermore, the % pattern 4 is required for GS 7
(3+4) in the College of American Pathologists checklists and
is recommended by the ICCR prostate datasets.15–18,27
Table 1 Controversial issues in Gleason grading
Issues in Gleason grading
 Percentage (%) pattern 4 in Gleason score 7
 Percentage (%) patterns 4 and 5 or 4/5 in Gleason score 8–10
 Minor high-grade or low-grade patterns when two Gleason grades are present (NB, TUR/SP, RP)
 Minor (5%) and non-minor (6–33%) high-grade patterns (Gleason 5) when three grades are present (NB, TUR/SP, RP)
 Level of reporting Gleason score and derivatives (core, specimen, case)
 Dealing with grade diversity among cores/specimens
 Dealing with grade diversity in multifocal tumours in RP (dominant nodule issue)
NB, needle biopsy; RP, radical prostatectomy; TUR/SP, transurethral resection/simple prostatectomy.
Fig. 1 Novel Gleason diagram from the 2014 ISUP consensus conference. Note absence of any cribriform pattern in grade 3.
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The measurement of % pattern 4 has greatest value in the
low range of GS 3+4=7. Most patients being considered for
active surveillance have GS 3+3=6; however, there are some
protocols which permit consideration of patients with GS
3+4=7 when there is a small amount of pattern 4.28 Recently,
in a guideline developed by Cancer Care Ontario and
endorsed by the American Society of Clinical Oncology it
was recommended that some patients with GS 3+4=7 and
10% pattern 4 be considered for active surveillance if other
factors, including serum prostate specific antigen (PSA) and
biopsy extent measurements are favourable.3
In borderline cases between GS 3+4=7 and GS 4+3=7, the
recording of the % pattern 4 provides greater transparency
regarding the subjectivity of the assignment. For instance, a
GS 3+4=7 tumour with 45–50% pattern 4 differs little from a
GS 4+3=7 tumour with 50–55% pattern 4. Similarly, at the
high end of the range, it is useful to know if the prostate
cancer is GS 4+3=7 (ISUP grade 3) with 90% pattern 4 and
10% pattern 3 which is close on the scale to a tumour with
>95% pattern 4 and 5% pattern 3. The latter would be
graded as GS 4+4=8 (ISUP grade 4) using a rule established
at the 2005 ISUP consensus meeting.2
In Gleason score 7 cases showing grade heterogeneity
among sites, the % pattern 4, if reported at case level (see later
discussion) can provide important information; for instance,
if there are multiple sites involved, with a mixture of GS
3+3=6, 3+4=7 and 4+3=7 tumour, many urologists and on-
cologists, and especially those in North America, would take
GS 4+3=7 as the definitive grade for treatment purposes.29
There may only be a single site with GS 4+3=7 tumour in
a core with minimal cancer involvement, say 10%. In such a
case, the overall % pattern 4 could be less than 5%. In
contrast if all sites show GS 4+3=7, then the overall % pattern
4 would range from 50–95%. The % pattern 4 measurement
allows urologists and oncologists to better understand the
actual amount of high grade tumour present in the biopsy.
There are several questions that arise relating to the
reporting of % Gleason pattern 4. Should this measurement
be reported at core, specimen or case level (see later section)?
Should the amount of pattern 4 be measured as a percentage
by linear extent or surface area, or as an actual length in
millimeters? Should the cellular density be considered and
how does one deal with intimately admixed patterns 3 and 4?
Is the % pattern 4 measurement reproducible? At present
there are no satisfactory data to provide evidenced based
answers to these questions. Future research studies need to be
designed and executed to advance the field.
It is proposed that at the very least the % pattern 4 mea-
surement should be reported at case level with core and
specimen level reporting being optional depending on local
practice patterns and clinical expectations. Since % linear
involvement and/or linear millimeters are recommended as
general tumour extent measures, the % pattern 4 can be
derived using similar techniques. Future research and
consensus activities will address that importance of identi-
fying and measuring sub-patterns of Gleason grade 4.
Regarding the stratification of % pattern 4, there are many
potential methods. Since 5% is used in the definition of a
‘minor high-grade pattern’, this category should be captured
in the measurement system.1 Additionally, since 10% is
incorporated into some active surveillance protocols, this
fraction should also be captured.3 It is suggested that the scale
be as follows: 5%, 6–10%, 11–20% and subsequent
deciles up to 91–100%. A further issue relates to whether
there should be a certain amount of tumour present in a core
to accurately assign % pattern 4. It can be difficult to decide
whether a very small focus of cancer in a needle core is GS
3+4=7 or 4+3=7, let alone to measure % pattern 4.30 It has
been suggested that because of lack of reproducibility, the
assignment of % pattern 4 should be considered optional in
small foci of Gleason score 7 adenocarcinoma.30 While
arbitrary, a small focus may be defined as 3 mm or less.
Finally, % pattern 4 has to be interpreted in the context of
tumour extent, as 90% pattern 4 in a 4 mm focus would not
have the same prognostic significance as 90% pattern 4 in a
20 mm focus. In such cases, the minute size of the malignant
focus and the associated uncertainty concerning the assigned
Gleason score may be addressed in a supporting comment.
PERCENTAGE (%) PATTERNS 4 AND 5 OR 4/5
IN GLEASON SCORE 8–10 CASES
McNeal et al. first proposed the reporting of % 4/5 in 1990
and later showed that this parameter was an independent
predictor of recurrence after radical prostatectomy.24,26,31
These authors also reported that nodal metastases occurred,
with only one exception, in patients with3.2 mL of Gleason
4/5 in their radical prostatectomy specimens.24 In a watchful
waiting cohort with long term follow-up, in which tumour
was diagnosed at time of transurethral resection, the % 4/5
was found to be an independent predictor of adverse sur-
vival.32 Sauter et al. in a recent study showed the value of
quantitative Gleason grading by recording the fraction of
Gleason patterns 3, 4 and 5 in a large series of radical pros-
tatectomy specimens.25 The authors emphasised that Gleason
grade represents a continuum and that the quantitative
approach provides prognostic information beyond that of
ISUP grades.
In Gleason score 7 cases, the % patterns 4/5 equates with %
pattern 4 and is discussed in an earlier section. The reporting
of % pattern 4/5 in GS 7 cases could cause confusion for
some clinicians who may wonder why pattern 5 is mentioned
at all; however, it is easy to explain that % pattern 4/5 = %
pattern 4 and/or pattern 5.
Is there a value in reporting the % 4/5 in cases with scores
8–10? In biopsy cases, there is large variation in the amounts
of high-grade cancer that may be present. This can present
problems when there is grade diversity among cores and
when grading is based on the core with the highest Gleason
score. A case could be classified as Gleason score 8 (ISUP
Grade 4) when one site shows GS 4+4=8 while all other
positive cores show mixtures of 3+3=6, 3+4=7 and 4+3=7. If
the core with GS 4+4=8 is only minimally involved by
cancer, the overall % 4/5 may be less than 5%. This differs
from the case where all involved sites show GS 4+4=8 and
the % 4/5 is 100%. One would expect the behaviour of these
latter tumours to be different from that of the former tumour
and yet both are classified as GS 4+4=8 for treatment pur-
poses if the highest Gleason score is used. The % 4/5 metric
also permits stratification of the uncommon GS 3+5=8 and
5+3=8 cases which can range from 3+5=8 with less than 5%
pattern 5 to 5+3=8 with 94% pattern 5. If there is 95% pattern
5, the tumour would be graded as 5+5=10 using the rules
established at the 2005 ISUP consensus conference.2
In biopsy cases where there are three grades present and the
highest grade is the third most common or tertiary pattern, the
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score encompasses the most common pattern and worst
pattern irrespective of the amount. If one site shows GS
4+5=9, 5+4=9 or 5+5=10 and the other sites have scores of 8
or less, the case would be scored as 9 or 10 for treatment
purposes if the highest Gleason score is used. If the core with
the highest score is only minimally involved by cancer, the
overall % 4/5 could be relatively low. This contrasts with the
situation where all cores are involved by GS 4+5=9, 5+4=9 or
5+5=10 tumour and the % 4/5 is 100%.
In radical prostatectomy specimens containing two grades,
the % 4/5 only provides additional information in the rare
situations where the Gleason scores are 3+5=8 and 5+3=8. In
situations where the scores are 4+4=8, 4+5=9, 5+4=9 or
5+5=10, no useful additional information is provided since,
by definition, they all have >95% patterns 4/5. However, if
three patterns are present, which may each theoretically
comprise 33.3% of the tumour, then the inclusion of % 4/5
would provide additional information to the Gleason score.
It is proposed that the % 4/5 measurement be performed in
a similar fashion to the % pattern 4 measurement and that this
be undertaken at case level. Core or specimen level reporting
of % 4/5 should be considered as optional. It is suggested that
the increments noted above for % pattern 4 also be used for %
4/5. In needle biopsies and radical prostatectomy specimens,
the inter- and intra-observer reproducibility of % pattern 4/5
is at least as good as that of the Gleason score.33,34 More
recently, the inter-observer reproducibility of % pattern 4 on
needle biopsies was found to be at a similar level, except in
cases with a minimal tumour focus.30
Another issue worthy of consideration is whether % pattern
4 and 5 should be separately documented. Earlier studies use
the combined % 4/5, while the more recent study by Sauter
et al. separately documented the percentages of patterns 3, 4
and 5.25,32 This latter approach provided additional prog-
nostic information, but from a practical perspective, there are
problems with borderline areas between pattern 4 and 5.
Furthermore, the additional burden of work is probably
beyond what should be expected from general surgical
pathologists.
MINOR HIGH-GRADE (AND LOW GRADE)
PATTERNS WITH TWO GRADES PRESENT
The issue of minor secondary patterns of higher grade in
biopsies was first addressed at the 2005 ISUP consensus
conference.2 A minor pattern is defined as one that accounts
for 5% of the tumour. At the consensus conference it was
agreed that when a minor high-grade pattern (pattern 4 or 5) is
present in a cancer with predominantly Gleason pattern 3 on
needle biopsy then the high-grade pattern should be included
in the score. However, if a minor low-grade pattern is present
in a tumour that is predominantly high grade (pattern 4 or 5)
then it should be omitted from the score. While the handling
of a transurethral resection and simple prostatectomy speci-
mens with minor high-grade patterns was not specifically
addressed, the rules for biopsies are generally used.
The method of dealing with minor high grade patterns in
radical prostatectomies was not specifically addressed at the
2005 conference.2 Some pathologists follow the rules for
needle biopsy and routinely include minor secondary high
grade patterns in the Gleason scores, while others prefer to
consider the minor secondary pattern as a ‘tertiary’ pattern
(see next section). This means that if a tumour was 95%
pattern 3 and 5% pattern 4, the former pathologists would
score the tumour as GS 3+4=7 while the latter would call it
GS 3+3=6 with tertiary 4.
It is proposed that when only two grades are present and
one is a minor high-grade pattern, this should be recorded in
all radical prostatectomy cases and may be included in the
Gleason score. There is some concern that the latter option
will result in significant grade inflation and the option re-
mains to record the Gleason score as 6 (3+3) with a minor
component of pattern 4. As long as the presence of a minor
high grade pattern is captured, it would be easy to compare
radical prostatectomy cohorts reported as GS 3+3=6 with a
minor component of pattern 4 with GS 3+4=7 with 5%
pattern 4. Importantly, pathologists should be conservative in
assigning pattern 4 in cases where the tumour is predomi-
nantly pattern 3. The identification of pattern 4 should be
undertaken at low power. The recognition of a few ill-defined
glands or borderline gland fusion on high power should not
be equated with pattern 4 (Fig. 2A,B). Likewise, pathologists
should be cautious in the diagnosis of small foci of Gleason
pattern 5 and not overcall tangentially cut ill-formed glands
of pattern 4 (Fig. 2C,D).
When a minor low grade (5%) pattern is seen in a radical
prostatectomy, it should be ignored. For instance, if there is
95% pattern 4 and <5% pattern 3, the latter should not be
included in the score.
MINOR HIGH-GRADE PATTERNS WITH
THREE GRADES PRESENT
It is recognised that three or more grades can be present in
some prostate cancers and indeed this phenomenon was re-
ported by Gleason in his original series.35 The proportion of
cases showing tertiary patterns ranges up to 48%; however,
this varies from series to series depending on which definition
of tertiary grade is used.36 The concept of a ‘tertiary’ grade
evolved from the work of Pan et al. who defined tertiary
grade as a higher grade (4 and/or 5) which occupied <5% of
the overall tumour.37 Unfortunately, the term ‘tertiary’ was
used differently by other pathologists who interpreted the
word literally to mean the third pattern and hence only used
‘tertiary’ when three distinct patterns were present. Some
investigators included both tertiary high grade and low grade
patterns when three distinct patterns were present.38,39 The
usage of the term ‘tertiary’when only two patterns are present
is semantically incorrect. For instance, in a radical prosta-
tectomy with 95% pattern 3 and 5% pattern 4, the term ‘GS
3+3=6 with tertiary 4’ is illogical. For this reason, at the 2014
consensus conference, it was agreed that the term ‘minor
high-grade pattern’ would be used instead of ‘tertiary’. This
term works equally well in cases with either two or three
grades present.
In needle biopsies with three grades present (patterns 3, 4
and 5), minor high-grade patterns are routinely incorporated
into the Gleason score. The concept of reporting the primary
pattern (i.e., the most predominant) and the worst remaining
pattern was first introduced in 2000 in the College for
American Pathologists prostate cancer protocol.40 This
practice was subsequently endorsed at the 2005 ISUP
consensus conference.2 In an example where a tumour is 60%
pattern 4, 35% pattern 3 and <5% pattern 5, the score is re-
ported as GS 4+5=9. The same principles can be applied for
TURP and enucleation specimens.
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The handling of minor high-grade patterns in radical
prostatectomies is more problematic. At the 2005 ISUP
meeting it was decided that tertiary patterns should be sepa-
rately reported in a note, but not incorporated into the Glea-
son score.2 No explicit % cut-off was mentioned for
excluding a third (tertiary) pattern in the Gleason score.
Subsequent reporting protocols from the College of Amer-
ican Pathologists and other international colleges contained a
data element for tertiary pattern and suggested a cut-off of
5%.16,18,41 While there is some direction on dealing with
minor high grade patterns (5% volume), the situation where
pattern 5 was present as a third non-minor pattern, i.e.,
6–33% of the overall tumour, was not addressed. In this
situation some pathologists have included pattern 5 as the
secondary pattern while others have continued to list it as a
tertiary pattern and give some indication of the % pattern 5 in
the diagnostic field or in a comment section of the report. In
the WHO blue book, it has been suggested that when pattern
5 is the third most common pattern and occupies >5% of the
tumour it should be incorporated in the score, although this
recommendation was not specifically discussed at the WHO
consensus meeting.10 Further research needs to be undertaken
before a method of handling non-minor tertiary patterns in
radical prostatectomies can be fully endorsed.
There have been some recent studies suggesting that the
integration of minor (so-called tertiary) patterns into ISUP
grade can improve the accuracy of predicting PSA recurrence
following radical prostatectomy.42–44 However, for the time
being, the presence of a minor component of pattern 5 in a
Gleason score 7 case should not affect the assignment of
ISUP grade.
THE LEVEL OF BIOPSY REPORTING (CORE,
SPECIMEN, CASE)
There are significant variations in the number and distribution
of samples from the prostate gland and how these are labelled
and submitted to the laboratory. A typical prostate biopsy
case consists of 10–14 cores, but some protocols provide 15
or more cores. In addition to systematic biopsies, targeted
ultrasonic and magnetic resonance imaging (MRI) guided
biopsies are being taken with increased frequency. For a
typical 12 core systematic biopsy the sampled cores may be
received in 12 separate specimen containers with site-specific
labels, six containers with typical sextant designations each
containing two cores, or six cores in each of two containers
labelled left and right. From the technical quality perspective,
single core, site-specific labelled submission and blocking is
ideal, although two cores submission and blocking is
acceptable.45 If more than two cores are present in a
container, there is an increased risk of fragmentation which
leads to problems with the histological processing and
reporting.
The ISUP has recommended that Gleason grading be un-
dertaken at core level if the cores are separately identified.1,2
This approach has been endorsed by the WHO.10 This
recommendation is easily followed for single core, site-
specific labelled specimens or for cases in which multiple
Fig. 2 (A) Gleason pattern 3 with tangential cut (small area in lower right quadrant). Needle biopsy specimen. (B) Gleason pattern with focal 4 (poorly formed glands).
Needle biopsy specimen. (C) Gleason pattern 4 with tangential cut (strands of epithelium in centre). Radical prostatectomy specimen. (D) Gleason pattern 4 with focal 5
(single cells and strands in upper half of the field). Radical prostatectomy specimen.
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cores are labelled with different inks indicating their location,
but submitted in one specimen container. However, when
multiple unidentified cores are submitted in a single specimen
container and multiple cores contain cancer, the pathologist
may choose to report aggregated Gleason score and tumour
extent measurements for the entire specimen. Therefore, the
minimum reporting requirement is at the specimen
(container, jar, pot) level with more detailed reporting of
individual cores being considered optional (Table 2, Fig. 3).
In this situation, workload implications need to be consid-
ered. Most workload measurement systems use the specimen
as the unit of work and not individual pieces or fragments that
constitute a single specimen. The best way for the urologist to
ensure that reporting is at core level is to provide individual
labelled cores.
Case level reporting of prostate biopsy parameters, while
considered optional by many, is of great value to the urologist
or oncologist, especially when there are multiple cores
(specimens) involved by tumour.15,17,27 In case level report-
ing, the Gleason score and other Gleason derivatives,
including ISUP grade and % patterns 4 and 5 or % pattern 4/5
measurements are captured. This allows the clinician to view
all relevant information in one field of their report rather than
try to determine the Gleason score for treatment purposes, as
well as other measurements, by viewing individual core/
specimen diagnostic lines. The case level synopsis is also of
value when discussing results with patients and in assembling
data for use in nomograms. With respect to grading, the
following parameters should be included in a case level report:
Gleason score (including primary and worst remaining
pattern) and the ISUP grade. For Gleason 7 cases, a % pattern
4 measurement should be recorded (see previous section). For
Gleason scores 8 and above, % 4/5 or % 4 and % 5 individ-
ually may also be provided. In general, the highest Gleason
score is the one to be recorded in the case level summary;
however, in situations where there is grading diversity across
individual core/specimens and the highest Gleason score is
minor in extent, a composite Gleason score may also be re-
ported (see later discussion). Furthermore, in cases where
there is a mixture of systematic andMRI targeted biopsies, the
Gleason score of the positive targeted biopsies may be sepa-
rately recorded in the case summary.
It is proposed that when a case level summary, which
includes a Gleason score and derivative measurements, is
used, it is not necessary to record the derivative measure-
ments including ISUP grade, and % patterns 4 and 5 or 4/5
at individual core/specimen level. A simple diagnostic line
to include the diagnosis, Gleason score (primary, worst
remaining) and relevant extent measures would suffice.
However, if a case level report is not utilised, Gleason score
and all relevant derivative measurements should be included
at the core/specimen level. It should be noted that the
amount of information provided on a per core basis can be
overwhelming, with more than 10 discrete data components
(Gleason score, primary grade, worst remaining grade, ISUP
grade, % pattern 4 and 5 or % pattern 4/5, number of pos-
itive cores, total cores, percent tissue involvement, linear
millimetres of tissue involvement, perineural invasion, peri-
prostatic fat invasion). In the case of 12 positive biopsies,
the amount of information for clinicians to assimilate can be
staggering, especially when there is inter-site grade di-
versity. A case level report helps to synthesise and thus
simplify the recording of relevant prognostic factors for
clinical usage.
DIVERSITY IN GLEASON SCORES AMONG
CORES (HIGHEST VERSUS COMPOSITE
GRADE)
In biopsy cases, it is not uncommon for cores to have
different Gleason scores. When the cores are submitted in a
fashion that allows their separate identification, the urologist
or oncologist may be faced with three or more separate scores
from which to choose the score for treatment purposes. At the
2014 consensus meeting, it was reported that the majority of
clinicians present at the meeting used the highest (worst)
score for treatment planning and prognostication. While this
approach is the norm in North America, in Europe and
elsewhere it is common for pathologists to report a global
(overall, composite) Gleason score for a biopsy case.29,46
This observation has been reinforced in a recent survey of
European uropathologists, where it was reported that 77% of
participants calculated a global score.46
The arguments in favour of taking the highest Gleason
score as the score for the case are anchored in the belief by
many clinicians that prostate cancer is multifocal and that its
behaviour is determined by the highest-grade element, akin to
other genitourinary tumours such as urothelial malignancy
and renal cell carcinoma. However, this belief is completely
contrary to the fundamental principle of the Gleason system,
i.e., that the behaviour of prostatic adenocarcinoma is based
on the relative proportions of various histological patterns
and not solely on the worst pattern. Some studies have shown
that the highest score in a core better correlates with radical
prostatectomy stage and Gleason score than the average or
most prevalent score among cores.47,48 In other studies, the
overall Gleason score performed in a similar fashion or better
than worst Gleason score, when biochemical recurrence or
cancer death rates were used as endpoints.49,50 It is interesting
to note that many risk calculators including the Partin tables,
were constructed and validated using the highest Gleason
score.51
Table 2 Needle biopsies: reporting levels for Gleason score and derivatives
Level of reporting Parameters
Gleason score ISUP grade % pattern 4 (Gleason 7) % patterns 4 and 5 or 4/5 (Gleason 8–10)
Core (separately identified) Recommended Optional if reported at case level Optional if reported at case level Optional if reported at case level
Specimen Recommended Optional if reported at case level Optional if reported at case level Optional if reported at case level
Casea Recommended Recommended Recommended Recommended
a Case level reporting is optional but when used it should include listed parameters.
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The practice of using the highest Gleason score has un-
doubtedly contributed to the recent trend of Gleason grade
inflation52 and it can also lead to significant downgrading at
the time of radical prostatectomy.47,53 In individual patients,
the reporting of highest Gleason score (without qualification
in a comment) can be misleading. They would likely be
classified as high risk and be subject to additional imaging
and more aggressive treatment options compared to those
with intermediate risk disease.54
In the scenario where multiple sites were involved by
Gleason score 3+4=7 and one site showed a small focus of
Gleason score 4+4=8 (Fig. 4), a slim, but not consensus level
majority (51%) of attendees at the 2014 consensus confer-
ence considered Gleason 3+4=7 as the score for treatment
purposes, even though one core contained low volume
Gleason score 8 cancer. When asked about the most likely
score at radical prostatectomy, 75% responded with GS
3+4=7. In situations where there is grade diversity among
cores, it may be worthwhile to provide a composite Gleason
score in a comment or case level synopsis.
GRADING OF SEPARATE TUMOUR FOCI IN
RADICAL PROSTATECTOMY SPECIMENS
One of the unique features of acinar adenocarcinoma of the
prostate is its remarkable multifocality. It has been reported
that up to 88% of these cancers have more than one tumour
focus.55,56 In only 9% of the patients, all foci were of the
same Gleason score.55 This adds to the challenges of grading
prostate cancer.
At the 2009 ISUP Consensus Conference on Handling and
Reporting of Radical Prostatectomy Specimens, it was
recommended that the dominant tumour nodule(s) of
multifocal cancer be graded separately.57 The rationale for
this is the assumption that an additional low-grade tumour
does not improve the prognosis of a tumour of higher grade.
For example, if a peripheral zone cancer is GS 4+4=8 and a
separate transition zone cancer is GS 3+3=6, then including
all cancer in a single score would result in a global GS of
3+4=7 or 4+3=7, depending on the size of the nodules. Such




Include GS, ISUP grade, %4 or %4/5
Are cores separately identified Are cores separately identified
















GS, ISUP grade, %4 or %4/5






Fig. 3 Algorithm for reporting Gleason score (GS), ISUP grade and derivative measurements at case, specimen and core level.
Fig. 4 Schematic showing situation where three biopsies from contiguous sites
show grade diversity. A small focus of Gleason score 4+4=8 is noted in the left
medial base site while left lateral base site shows abundant Gleason score
3+3=6. The lateral mid site contains a small amount of Gleason score 3+4=7
tumour. The composite Gleason score in this situation would be 3+4 =7 with
less than 10% pattern 4. If the highest Gleason score is used for treatment
purposes, the patient would be classified as high risk (Gleason 8–10). If this
patient underwent radical prostatectomy, the Gleason score would likely be
3+4=7.
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a grade dilution of the GS may not accurately reflect the
outcome. However, there are several problems with this
approach. First of all, there is disagreement as to the defini-
tion of dominant tumour or index tumour as defined at the
2009 ISUP conference.57 In most cases the largest focus also
has the highest grade but occasionally a small tumour has a
higher grade than a much larger, low-grade tumour. In one
study, a discordance between highest GS, largest tumour
volume and extraprostatic extension was noted in 11.3% of
multifocal cancers on radical prostatectomy.56 A very large
low-grade tumour may be more important prognostically than
a minimal tumour of higher grade, but it is impossible to be
sure of this in the individual patient. A similar situation
occurs when a tumour of lower grade has extra-prostatic
extension while a high-grade tumour focus is organ-confined.
The growth pattern of prostate cancer is highly infiltrating
and branching. It may be difficult to determine if tumour
areas are from separate foci or parts of the same tumour
nodule. When a radical prostatectomy specimen is partially
embedded as practised in some laboratories, it is very diffi-
cult, if not impossible, to determine if the tumour is multi-
focal. Whole mount sections of horizontal slices of entire
prostatectomy specimens greatly facilitate the reconstruction
of the three-dimensional structure of the tumour (or tumours).
However, not all laboratories have sufficient resources for
whole mounting and this technique also has certain technical
disadvantages relating to transportation of slides, re-cutting
for immunohistochemical evaluation and archiving of
slides.58
The remarkable morphological heterogeneity of prostate
cancer is paralleled by a genetic heterogeneity. It has been
shown that spatially separated tumour foci are somatically
independent,59 but there is also a pronounced intra-tumoural
genetic heterogeneity.60 When tumour foci enlarge, they will
ultimately merge into what seems to be one single focus.
Intra-tumoural morphological heterogeneity may suggest that
separate foci have merged but given the inherent heteroge-
neity of prostate cancer it is indeed difficult to be certain of it.
Occasionally the findings may be quite compelling for
merging of foci, e.g., when there is one tumour component in
the peripheral zone and an adjacent component in the tran-
sition zone with contrasting grade and morphology.
The notion that the tumour of the highest grade must be
most important for the patient has been challenged in recent
genetic analyses. In one study, whole-genome sequencing
was used for tracking of the metastatic cancer clone of a
single case. Unexpectedly the lethal clone came from a small,
low-grade focus and not from a large higher-grade primary
cancer.61 Similarly, genetic mapping of a single case of
prostate cancer with lymph node metastases revealed that the
metastases were not derived from invasive Gleason score 9
cancer but from a component of intra-ductal prostatic
adenocarcinoma.60 Thus, it may not be possible to identify
morphologically the clinically most important tumour clone.
Until there is evidence-based guidance as to how multifocal
and heterogeneous prostate cancer should be reported, it is
suggested that the tumour foci with the highest grades, vol-
umes and stages are reported separately. The importance of
total embedding of radical prostatectomy specimens should
be emphasised, as this greatly facilitates the mapping of the
spatial distribution of separate foci.62
SUMMARY AND RECOMMENDATIONS
The proposed recommendations for grading prostate cancer
(Table 3) deal with practical aspects of applying the Gleason
system in modern day practice. While some of these rec-
ommendations have been endorsed at the 2014 ISUP
consensus conference, many items were not fully discussed
or polled at the meeting. There is not a strong evidence base
for many of these guidelines. The proposed recommendations
mostly reflect expert opinion and they are classified as
established if there has been prior agreement by consensus
and provisional if there was no previous agreement or if the
item was not discussed at prior consensus conferences. Future
research and consensus activities will hopefully address some
Table 3 Summary of Established and Provisional Recommendations
Established and Provisional Recommendations
 Report Gleason score and ISUP grade in each positive case (E)
 Report Gleason score for every separately identified positive core (E)
 Report overall Gleason score when non-identified cores are aggregated in one specimen container; individual core reporting is optional (E)
 When case level report is used, Gleason score, ISUP grade and derivative measurements should be included in the summary; the Gleason score should also be
included at the core/specimen level (P)
 When case level report is not used, Gleason score, ISUP and derivative Gleason measurements should be included at the core/specimen level (E)
 For Gleason score 7 cases (ISUP grade 2 or 3) report % pattern 4 (E)
o Required for ISUP grade 2 and recommended for ISUP grade 3 (P)
 % pattern 4 should be quantified as follows: (5%, 6–10% and subsequent 10% increments) (P)
 For small foci of Gleason 7 (3 mm), % pattern 4 is considered optional (P)
 For Gleason scores 8–10 (ISUP grades 4,5), reporting % 4 and % 5 or % 4/5 is considered optional but may be of value, especially in cases showing grade
heterogeneity (P)
 Minor low-grade patterns should not be included in the Gleason score in needle biopsy specimens (E) and other specimen types (P)
 Minor high-grade patterns should be included in the Gleason score when two patterns are seen in needle biopsy, TUR/SP specimens (E)
 Minor high-grade patterns should be recorded when 2 patterns are seen in RP specimens and may be included in the Gleason score (P)
 A minor high-grade pattern should be included in the Gleason score when 3 grades are present in NB, TUR/SP specimens (E)
 When three grades are present in a RP and pattern 5 is 5%, it should not be included in the Gleason score; the % pattern 5 should be recorded separately (E)
 When 3 grades are present in a RP and pattern 5 is 6–33%, it may be included in the Gleason score; the % pattern 5 should also be recorded separately (P)
 When there is grade diversity across sites, a composite Gleason score may be generated which should be included in the case level report or in a comment (P)
 In RP specimens with multifocal adenocarcinoma, Gleason score and derivative measurements should be given for the dominant tumour nodule(s) (E)
 In RP specimens with diffuse or multifocal adenocarcinoma where a dominant nodule is not clearly identified, the Gleason score and derivatives should be
based on all identified tumour (P)
(E), Established recommendation through prior consensus activities; (P), provisional recommendation: further research and consensus required. NB, needle biopsy;
RP, radical prostatectomy; TUR/SP, transurethral resection/simple prostatectomy.
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of the deficiencies, for instance in the handling of tertiary
patterns in radical prostatectomy cases. However, for the time
being the proposed recommendation framework is pragmatic
and will help ensure some uniformity of approach moving
forward. The proposed recommendations also allow some
flexibility in reporting which reflects the variation in uro-
logical pathology practice internationally.
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